Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 2, 2013, Pages 118-123

  Rutter, K ^a   Hofer, H ^a   Beinhardt, S ^a   Dulic, M ^b   Gschwantler, M ^b   Maieron, A ^c   Laferl, H ^a   Stattermayer A F ^a   Scherzer, T M ^a   Strassl, R ^a   Holzmann, H ^a   Steindl Munda, P ^a   Ferenci, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c Hospital of Elisabethinen   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BALAPIRAVIR; DANOPREVIR; FALDAPREVIR; MERICITABINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RITONAVIR; SIMEPREVIR; TELAPREVIR; ALPHA INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEQUENCE ANALYSIS; TREATMENT RESPONSE; VIRUS RESISTANCE; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84879218816     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12350     Document Type: Article

References (29)

1. Marcellin P, Boyer N, Gervais A, et al,. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.
2. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O,. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783-7.
3. Formann E, Steindl-Munda P, Hofer H, et al,. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23: 507-11.
4. Swain MG, Lai MY, Shiffman ML, et al,. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.
5. Veldt BJ, Heathcote EJ, Wedemeyer H, et al,. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
6. van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
7. Bruno S, Stroffolini T, Colombo M, et al,. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
8. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS,. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-8, 288 e1.
9. Yoshida H, Arakawa Y, Sata M, et al,. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
10. Innes HA, Hutchinson SJ, Allen S, et al,. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011; 54: 1547-58.
11. Bonkovsky HL, Woolley JM,. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-70.
12. D'Ambrosio R, Aghemo A, Rumi MG, et al,. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-43.
13. Poynard T, McHutchison J, Manns M, et al,. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
14. Shiratori Y, Imazeki F, Moriyama M, et al,. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
15. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
16. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
17. Lee SS, Roberts SK, Berak H, et al,. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. Liver Int 2012; 32: 1270-7.
18. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
19. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
20. Marcellin P, Forns X, Goeser T, et al,. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-68.
21. Sulkowski M AT, Lalezari J, Ferenci P, Fainboim H, Muñizi FJ, Leggett B,. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 Trial. Hepatology 2013; doi: 10.1002/hep.26276.
22. Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C,. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial. J Hepatol 2013; 58 (Suppl. 1): S569-70.
23. Manns M, Marcellin P, Poordad F, Affonso de Araujo S, Buti M, Horsmans Y,. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S568.
24. Wedemeyer H, Jensen D, Herring R Jr, et al,. PROPEL: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 2013; doi: 10.1002/hep.26274.
25. Nelson DR, Zeuzem S, Andreone P, et al,. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol 2012; 11: 15-31.
26. Stättermayer AF, Stauber R, Hofer H, et al,. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-50 e2.
27. Lawitz E PF, Kowdley KV, Jensen D, Cohen DE, Siggelkow S,. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naïve HCV IL28B-CC genotype-1-infected subjects. J Hepatol 2012; 56 (Suppl. 2): S7.
28. De Marco L, Manzini P, Trevisan M, et al,. Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS ONE 2012; 7: e43541.
29. Rutter K, Stättermayer AF, Ferenci P, et al,. Successful HCV eradication due to antiviral therapy is associated with improved long term outcome of patients with chronic hepatitis C. J Hepatol 2013; 58 (Suppl. 1): S369.